Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease : A single lipid center real-world experience

Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved..

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) may be crucial in subjects with familial hypercholesterolemia (FH). We aimed to evaluate the effect of the inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9-i) on steatosis biomarkers such as triglyceride-glucose index (TyG) and hepatic steatosis index (HSI) and analyse the role of TG/HDL in this population before and after adding-on PCSK9-i.

METHODS AND RESULTS: In this observational study, we evaluated 26 genetically confirmed FH patients with NAFLD and an LDL-C off-target despite high-intensity statins plus ezetimibe. All patients added PCSK9-i treatment and obtained biochemical analysis and TyG and HSI evaluation at baseline and after six months of PCSK9-i. No difference of steatosis biomarkers was found after adding-on PCSK9-i therapy. In a secondary analysis, we divided the study population in two groups according to TG/HDL median value: high TG/HDL group (H-TG/HDL) and low TG/HDL group (L-TG/HDL). TyG and HSI were significantly lower in the L-TG/HDL than H-TG/HDL group (for TyG 9.05 ± 0.34 vs 9.51 ± 0.32; for HSI 38.43 ± 1.35 vs 41.35 ± 1.83, p value for both < 0.05). After six months of PCSK9-i therapy, TyG and HSI were significantly reduced in the L-TG/HDL group after PCSK9-i therapy (-7.5% and -8.4% respectively, p value for both < 0.05) and these biomarkers were lower compared to H-TG/HDL group (for TyG 8.37 ± 0.14 vs 9.19 ± 0.12; for HSI 35.19 ± 1.32 vs 39.48 ± 1.33, p value for both < 0.05).

CONCLUSION: In conclusion, PCSK9-i therapy significantly ameliorate steatosis biomarkers in FH patients with low TG/HDL; our results appear to be consistent with a beneficial role of PCSK9-i on steatosis biomarkers in FH subjects with NAFLD.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:31

Enthalten in:

Nutrition, metabolism, and cardiovascular diseases : NMCD - 31(2021), 3 vom: 10. März, Seite 869-879

Sprache:

Englisch

Beteiligte Personen:

Scicali, Roberto [VerfasserIn]
Di Pino, Antonino [VerfasserIn]
Urbano, Francesca [VerfasserIn]
Ferrara, Viviana [VerfasserIn]
Marchisello, Simona [VerfasserIn]
Di Mauro, Stefania [VerfasserIn]
Scamporrino, Alessandra [VerfasserIn]
Filippello, Agnese [VerfasserIn]
Rabuazzo, Agata M [VerfasserIn]
Purrello, Francesco [VerfasserIn]
Piro, Salvatore [VerfasserIn]

Links:

Volltext

Themen:

Anticholesteremic Agents
Biomarkers
Blood Glucose
Cholesterol, HDL
Cholesterol, LDL
EC 3.4.21.-
EOR26LQQ24
EsRAGE
Ezetimibe
Familial hypercholesterolemia
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inflammation Mediators
Journal Article
Lipids
NAFLD
Observational Study
PCSK9 Inhibitors
PCSK9 inhibitors
PCSK9 protein, human
Research Support, Non-U.S. Gov't
Serine Proteinase Inhibitors
Steatosis biomarkers
TG/HDL
Triglycerides

Anmerkungen:

Date Completed 17.03.2021

Date Revised 04.12.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.numecd.2020.11.009

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM321099737